Cutaneous manifestations of Nilotinib

Abstract

Nilotinib is a highly selective second-generation Bcr-Abl tyrosine kinaseInhibitor (TKIs), which is effective in patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML). Tyrosine kinase inhibitors have broadly similar types of non-hematological adverse side effects (AES), but some of the AES are specific to one drug compared to the others. In general, the TKIs are well tolerated with mostly (grade1-2) toxicities, and relatively limited grade (34) toxicities. For best management of CML patients receiving TKI therapy, early recognition and knowledge of potential toxicities are required, allowing for optimal management of the condition without interruption of the drug.